610
Participants
Start Date
September 17, 2021
Primary Completion Date
April 18, 2025
Study Completion Date
October 18, 2025
AK104
AK104 (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward, AK104 will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
Placebo
Placebo (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward,Placebo will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)
Zhongshan Hospital, Fudan University, Shanghai
Peking University Cancer Hospital, Beijing
Fudan University Cancer Hospital, Shanghai
The First Affiliated Hospital of Zhejiang University Medical College, Hangzhou
Fujian Provincial Cancer Hospital, Fuzhou
West China Hospital of Sichuan University, Chengdu
Yunnan Cancer Hospital, Kunming
Lead Sponsor
Akeso
INDUSTRY